A pivotal trial of obinutuzumab has demonstrated the strongest evidence yet of the efficacy of B-cell depletion in systemic ...
The consistency of results across racial groups suggests that, within the controlled setting of clinical trials, ...
A multicenter, single-arm, phase 2 trial investigated the activity and safety of varnimcabtagene autoleucel in adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
Please provide your email address to receive an email when new articles are posted on . WASHINGTON — Inebilizumab is safe and effective in IgG4-related disease, significantly reducing the chance of ...
SAVANNAH, Georgia — Inebilizumab, a first-in-class anti-CD19 B-cell depleting agent, demonstrated both safety and superior efficacy compared with placebo in patients with seropositive generalized ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results